B
GLUE icon

Bailard’s Monte Rosa Therapeutics GLUE Stock Holding History

Bailard’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,500
Closed -$167K – 805
2025
Q3 		$167K Hold
22,500
– – ﹤0.01% 744
2025
Q2 		$101K Buy
+22,500
New +$100K ﹤0.01% 738

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bailard's GLUE Position: Q4 2025 in Review

Bailard sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 22,500 shares — an estimated $167K sold.

Bailard first reported a position in GLUE in Q2 2025 and held it in 2 quarters. The position peaked at $167K in Q3 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Bailard reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bailard sold 22,500 Monte Rosa Therapeutics shares in Q4 2025, an estimated $167K.
  • Bailard first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 2 quarters.
  • Bailard's Monte Rosa Therapeutics position peaked at $167K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.